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Abstract
Background
Major depressive disorder (MDD) associated with chronic neglected tropical diseases
(NTDs) has been identified as a significant and overlooked contributor to overall disease
burden. Cutaneous leishmaniasis (CL) is one of the most prevalent and stigmatising NTDs,
with an incidence of around 1 million new cases of active CL infection annually. However,
the characteristic residual scarring (inactive CL) following almost all cases of active CL has
only recently been recognised as part of the CL disease spectrum due to its lasting psycho-
social impact.
Methods and findings
We performed a multi-language systematic review of the psychosocial impact of active and
inactive CL. We estimated inactive CL (iCL) prevalence for the first time using reported
WHO active CL (aCL) incidence data that were adjusted for life expectancy and underre-
porting. We then quantified the disability (YLD) burden of co-morbid MDD in CL using MDD
disability weights at three severity levels. Overall, we identified 29 studies of CL psychologi-
cal impact from 5 WHO regions, representing 11 of the 50 highest burden countries for CL.
We conservatively calculated the disability burden of co-morbid MDD in CL to be 1.9 million
YLDs, which equaled the overall (DALY) disease burden (assuming no excess mortality in
depressed CL patients). Thus, upon inclusion of co-morbid MDD alone in both active and
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inactive CL, the DALY burden was seven times higher than the latest 2016 Global Burden of
Disease study estimates, which notably omitted both psychological impact and inactive CL.
Conclusions
Failure to include co-morbid MDD and the lasting sequelae of chronic NTDs, as exemplified
by CL, leads to large underestimates of overall disease burden.
Author summary
Cutaneous leishmaniasis is a highly prevalent vector-borne disease affecting large parts of
Latin America and the Middle East, as well as parts of Northern Africa. There are several
types of Cutaneous leishmaniasis, almost all of which have an active phase characterized
by a disfiguring lesion (typically on exposed parts of the body), which then becomes a per-
manent scar (the inactive phase). We recently published an article highlighting the impact
of the inactive scarring phase of CL on affected individuals, which is associated with high
levels of stigma. Nevertheless, this aspect of the disease is not considered in its own right
when calculating the overall disease burden by the Global Burden of Disease (GBD) Stud-
ies. In this article we estimate the prevalence of depression (major depressive disorder) in
cutaneous leishmaniasis, in both the active and inactive forms. We then show the contri-
bution of inactive CL to the overall disease burden estimates when included, which is due
to the large psychological impact it has on those affected by it. We also highlight the
importance of further similar efforts for other NTDs which have a chronic course, and
which are also not sufficiently included in disease burden calculations at present.
Introduction
Cutaneous leishmaniasis
Cutaneous leishmaniasis (CL) is the most prevalent form of leishmaniasis and 1 of 22 highly
prevalent neglected tropical diseases (NTD) [1]. Current disease classifications differentiate
aspects of the active (nodular, ulcerative or plaque) CL lesion in terms of its transmission route
(“zoonotic” vs “anthroponotic”), geographical location (“New World” vs “Old World”), and
extent of its dermatological manifestations (“diffuse” vs “localised”) [2]. However, none cap-
ture the characteristic stigmatisation and psychological sequelae of life-long residual CL scar-
ring that accompanies active infection in almost all cases. As such, we recently expanded the
spectrum of CL disease by introducing new terminology—active (aCL) and inactive (iCL) scar-
ring cutaneous leishmaniasis—to describe the dermatological changes of CL in relation to its
disease activity [3]. Such a classification is also inclusive of long-term sequelae such as muco-
cutaneous leishmaniasis (MCL), which develops in a minority of CL cases (~4%) [4] mainly in
the Americas and East African regions and which may represent a reactive form of CL [5].
The stigmatisation resulting from visible active and inactive CL lesions can be traced back
centuries and was probably a major driver in establishing the ancient practice of leishmanisa-
tion [6]. Nevertheless, this defining psychosocial aspect of cutaneous leishmaniasis has been
almost completely overlooked by successive disease burden studies [7–10]. Furthermore, the
prevalence of inactive CL has not previously been estimated and as such is not presently incor-
porated into burden estimates. This unfortunately underlines a habitual lack of consideration
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for the chronic sequelae of NTDs. Regrettably, as CL is not a life-limiting infection, policy-
makers often neglect CL as a priority disease [11–13] despite its importance to endemic com-
munities and its links to poverty [14]. This oversight is particularly problematic given the
increasing CL incidence in highly endemic conflict zones of Afghanistan, Iraq, the Syrian Arab
Republic, and Yemen, creating a major public health problem [15,16].
Major depressive disorder (“depression”)
Major Depressive Disorder (MDD) is the most prevalent form of mental disorder, affecting
4.4% of world’s population [17]. The diagnosis of MDD is symptom-based and follows the Dis-
ease Statistical Manual (DSM). MDD is one of two depressive disorders that account for the
fifth largest cause of disability (years of life lived with disability; YLD) in the latest 2016 Global
Burden of Disease (GBD) Study [18]. There is also a growing recognition by the global mental
health community of the importance of adopting a more inclusive approach to mental health
and disease, from wellness to subclinical distress to clinical “disorder”, known as the staged
model of depression [19].
The psychological impact of the NTDs is an area that has only recently been emphasised in
the NTD community [20]. For example, mental ill health was not included in recent calcula-
tions of disability-adjusted life years (DALYs) averted by NTD programmes, suggesting that
the psychological impact of these conditions is not a primary outcome of such programmes
[21]. It is therefore unsurprising that previous global burden of depression studies appear to
exclude NTDs from their prevalence and burden estimates [17,22,23] This omission is highly
significant for two reasons: Many of NTDs are uniquely stigmatizing [20], and collectively,
WHO estimates that NTDs affect over 1 billion (or 1 in 6) people worldwide [1].
In summary, CL is often ignored at the policy level due to its lack of mortality, and is there-
fore a prime example of a stigmatising, prevalent NTD whose associated mental illness is disre-
garded. The aims of the present study are two-fold: 1) To conduct a systematic review of the
psychological impact of cutaneous leishmaniasis; 2) To quantify the burden of co-morbid
major depressive disorder in this highly prevalent and stigmatising condition for the first time.
Methods
Our study reflects the current approach to disease burden estimates, which are based upon
MDD as classified by the DSM [22]. We have also adopted the staged model of depression to
use additional evidence from psychological and quality of life studies. These latter studies were
used to calculate stages of subclinical distress associated with CL and to quantify its overall psy-
chosocial impact.
There are four steps to calculating the burden of co-morbid depression (in DALYs) due to
CL. Firstly, we conducted a systematic review of the psychosocial impact of all forms of CL
(including MCL). To quantify the overall impact of iCL as part of the burden of CL, we also
had to generate estimates of iCL prevalence for the first time. Following these first two steps,
we then estimated the prevalence of MDD co-morbidity and its severity in aCL and iCL
patients. We did not calculate the burden of co-morbid MCL as the associated mortality rate is
not known and therefore prevalence estimates could not be reliably calculated. Finally, we
multiplied the prevalence of aCL and iCL with co-morbid MDD by the disability weight (DW)
for MDD at three severity levels (mild, moderate, and severe) following the methodology of
Ton et al (2015) [24] (see Fig 1).
The search strategy queried four Ovid databases–Medline [25], EMBASE [26], Global
Health [27], and PSYCInfo [28]–as well as LILACS [29], using English, French, Spanish, and
Portuguese search terms on 4th December 2017. Additional searches through Google Scholar
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[30] were performed in Arabic and English, along with back referencing of relevant articles
and a grey literature search. The search strategy accounted for common terms and abbrevia-
tions for cutaneous leishmaniasis (e.g. “CL” and “cutaneous leishmaniasis”), and combined
these with key words for major depressive disorder and its symptoms, as well as general psy-
chological impact (e.g. “psych�”, “major depressive disorder”, “distress”). We included all rele-
vant psychological studies in CL patients and those with reliable knowledge of their
experiences (i.e. their caregivers and their care providers) (Fig 2). As such, community studies
were excluded from our final analysis except to further contextualise our findings. Please see
S1 Appendix for further details of the search strategy and individual terms queried. Please see
S2 Appendix for our inclusion and exclusion criteria, and S3 Appendix for the reasons for
excluding studies from final analysis.
Results
Estimating major depressive disorder co-morbidity in cutaneous
leishmaniasis
Twenty-nine studies were included in the final analysis of the psychosocial impact of CL (see
S4 Appendix). The large majority (25/29) of studies were based in middle-income countries
(18/29 UMIC, 7/29 LMIC) [32]. Similarly, most studies took place in the highest burden world
regions (12/29 in the Eastern Mediterranean Region (EMR) and 11/29 in the Americas Region
(AMR)), and included 11 of the 50 highest burden countries for CL in the world [9].
Studies that quantified an MDD diagnosis or symptoms using both validated (e.g. SCID-1;
BDI) and unvalidated tools (e.g. self-reported depression symptoms) were used to determine
rates of co-morbid MDD in both aCL and iCL (See Table 1). Additional quality of life, stigma,
socioeconomic, and qualitative studies were used to generate an estimate of subclinical “dis-
tress” as per the staged model of depression (see Tables 2 and 3).
A diagnosis of MDD was consistently reached within the mean or one standard deviation
of the mean in CL patients [33,34,36,38], equating to MDD rates of 30–50%. Meanwhile, quan-
tification of symptoms of MDD mostly relied upon self-reporting. As such, symptoms of low
Fig 1. Modified disability-adjusted life years (DALY) model for calculating the burden of co-morbid conditions. Adapted from Ton et al (2015) [24].
https://doi.org/10.1371/journal.pntd.0007092.g001
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mood and depression in CL patients ranged from 12.5–90.9% [34,40–45] aCL patients had sig-
nificantly higher rates of MDD compared to controls in both children and adults [36] aCL was
also found on multivariate analysis to be an independent risk factor for mental disorder in the
primary care setting [33]. It is therefore unlikely that these results are a product of significant
selection bias.
Equally, whilst rates of MDD were not measured for children with iCL, significantly higher
rates of MDD were found in adults compared to controls. iCL patients were also at signifi-
cantly higher suicide risk than controls [34]. In the only study to measure co-morbid MDD in
both aCL and iCL, CL scarring was associated with non-statistically significantly higher MDD
scores [38]. These findings are important, as considerably more patients are in the inactive
(scarring) phase of CL than in the active phase. Although the data suggest that rates of MDD
in iCL are at least equal to those found in aCL patients, the majority of studies (16/29) focused
exclusively on aCL.
More broadly, quality of life was found to be significantly decreased in CL patients com-
pared with controls. Stigma was a characteristic feature of CL in most quantitative and qualita-
tive studies, whilst psychological distress was found to be between 50–90% [46,55]. Similarly,
issues of disfigurement and reduced capacity to work affected the majority of sufferers (see
Table 2). Interestingly, the psychological burden extended to CL caregivers, who were also
Fig 2. Prisma flowchart. [31].
https://doi.org/10.1371/journal.pntd.0007092.g002
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Table 1. Quantitative studies: MDD diagnosis and symptoms (validated and non-validated measures).
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample
size
Sex Age Lesion
location
Disease
activity
MDD
measure
Results Interpretation
MDD diagnosis: Validated measure
Simsek et al
(2008) [33]
Turkey
(EUR)
UMIC 64
(8 CL;
56 non-
CL
primary
care)
100% F
(Overall)
30
(Overall)
- aCL SCID-I
(mental
disorder)
CL: 53.3%
Non-CL: 24.1%
aCL: independent risk
factor for mental
disorder;
MDD most prevalent
mental disorder;
Multiple mental
disorders common
Torkashvand
et al (2016)
[34]
Iran
(EMR)
UMIC 160
(80 iCL;
80 former
CL, no
iCL)
43.1% F
(Overall)
31.01
mean
(Overall)
50% face;
50% rest
of body
iCL BDI BDI (mean):
Face:
11.66 ± 15.38
Body:
11.64 ± 14.11
No scar:
3.82 ± 8.09
0–13: Minimal 14–19:
Mild
20–28: Moderate 29–
63: Severe [35]
BDI severity:
Face: mild = 12.2%;
mod = 4.9%;
sev = 17.1%)
Body: mild = 7.7%;
mod = 15.4%;
sev = 12.8%
No scar = 3.8%;
mod = 6.3%;
sev = 2.5%
Turan et al
(2015) [36]
Turkey
(EUR)
UMIC 94
(54 CL;
40 healthy
controls)
54% F
(CL);
50% F
(Control)
7–12;
13–18
65% face aCL CDI
(Also QoL;
see below)
7–12 (mean):
aCL: 9.72 ± 6.11
Control:
4.5 ± 3.83
8–13 (mean):
aCL: 14.25 ± 4.76
Control:
4.50 ± 2.46
Clinical cut-off: 13
Community cut-off:
19 [37]
8–13: Over 50% met
clinical cut-off; those
within 1 SD of mean
met community cut-
off. Patients aged
7–12: Those within 1
SD of mean met
clinical cut-off; those
within 2 SD met
community cut-off
Significantly higher
than control at both
age groups
Yanik et al
(2004) [38]
Turkey
(EUR)
UMIC 99
(33 iCL;
33 aCL;
33 healthy
controls)
50.5% F
(Overall)
18
(Overall)
70% face
30% UL
(Overall)
aCL/
iCL
HADS-D
(Also QoL;
see below)
Mean aCL:
7.24 ± 3.91
Mean iCL:
8.67 ± 3.83
Mean control:
5.76 ± 4.01
Mild: 8–10 Moderate:
11–14; Severe: 15–21
[39]
aCL: Mean score on
cusp of mild MDD;
those within 1 SD of
mean met cut-off for
moderate MDD
iCL: Over 50% met
cut-off for mild MDD;
those within 1 SD of
mean met cut-off for
moderate MDD
Depression rates
significantly higher
CL vs control
MDD symptoms: Validated measure
(Continued)
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found to have significantly elevated depression rates [36] and diminished quality of life [36,49]
compared to controls.
Overall, CL is associated with a high degree of psychological morbidity irrespective of coun-
try, age, and disease activity. We present two other important patient- and disease-specific var-
iables considered during our analysis: patient sex and lesion location. These were chosen due
to multiple reports linking them with increased psychosocial impact. Indeed, despite findings
of qualitative studies that facial lesions are the most psychologically damaging [42,45,63,67],
Table 1. (Continued)
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample
size
Sex Age Lesion
location
Disease
activity
MDD
measure
Results Interpretation
Hono´rio et al
(2016) [40]
Brazil
(AMR)
UMIC 44 54.5% F 51.8 - aCL WHO-QoL
Bref
Q26 Negative
feelings (blue
mood, anxiety,
despair,
depression)
90.9%
Frequency:
18.18% always;
43.18% very often;
20.45% quite often;
9.09% seldom; 9.1%
never
Hu et al
(2015) [41]
Suriname
(AMR)
UMIC 163 8.3% F
7.6% F
7 day: 33
(median)
3 day: 30
(median)
7 day:
10.7%
face
13 day:
7.7% face
aCL EQ-5D
(Also QoL;
see below))
Depression/
Anxiety:
Pre-treatment:
50.6%
(7 day and 3 day)
Post-treatment
(6 wks):
7 day: 2.9; 3 day:
9.4%
Significantly reduced
symptoms of anxiety
and depression with
treatment (both 3-
and 7-day regimes)
Torkashvand
et al (2016)
[34]
Iran
(EMR)
UMIC 160
(80 iCL;
80 former
CL, no
iCL)
43.1% F
(Overall)
31.01
mean
(Overall)
50% face;
50% rest
of body
iCL BSQ BSQ (mean):
Face: 4.73 ± 9.59
Body: 5.89 ± 8.91
No scar:
1.22 ± 3.47
Suicide risk level:
Face: never = 78.0%;
low = 4.9%;
high = 17.1%
Body: never = 61.5%;
low = 12.8%;
high = 25.6%
No scar:
never = 87.5%;
low = 10.0%;
high = 2.5%
MDD diagnosis/symptoms: Non-validated measure
Al-Kamel
(2017) [42]
Yemen
(EMR)
LMIC 11 90.91% F 29.4
(mean)
38.5% UL
61.5%
face
aCL
72.7%
iCL
18.2%
MCL
9.1%
Depression 27.3% Self-reported
depression rates not
affected by presence
of MCL
Bastidas et al
(2008) [43]
Venezuela
(AMR)
UMIC 17 58.8% F 25–34
mode
- aCL/
iCL
Low mood Total: 58.8%
F: 100%
M: 0%
Marked sex difference
Pacheco et al
(2017) [44]
Brazil
(AMR)
UMIC 24 62.5% F 38.8 100%
exposed
aCL Sadness,
depression,
low mood
Total: 12.5%
(F: 33.3%; M:
0%)
Marked sex difference
Semeneh
(2012) [45]
Ethiopia
(AFR)
LIC 10 50% F 29.3 100% face aCL 30%
iCL
70%
High
depression
30%
BDI = Beck Depression Inventory; BSS = Beck Scale for Suicidal Ideation; CDI = Children’s Depression Inventory; EQ-5D = Euro-Qol-5 Dimensions;
HADS-D = Hospital Anxiety and Depression Scale–Depression; LIC = Low Income Country; LMIC = Lower-Middle Income Country; SCID-I = Systematic Clinical
Interview for Depression– 1st version; UMIC = Upper-Middle Income Country; WHO-QoL Bref = World Health Organization Quality of Life Short
https://doi.org/10.1371/journal.pntd.0007092.t001
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Table 2. Quantitative studies: Quality of life, psychological distress, stigma, socioeconomic impact studies.
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Measure Results Interpretation
Quality of life
Chahed et al
(2016) [46]
Tunisia
(EMR)
LMIC 41 100% F 85% <30 93% face
54% rest
of body
iCL WHO-QoL
Bref
Social
relationships: 63.0
Psychological:
52.6
Social: 61.8
Environmental:
47.8
Total: 56.3
Psychological
QoL on the verge
of significant
correlation with
PLSI (p <0.087)
Elsaie et al (2017)
[47]
Egypt
(EMR)
LMIC 12 16.7% F 32 -
(almost
all
exposed)
aCL DLQI Pre-treatment:
12.67
Post-treatment:
4.25
Pre-treatment:
very large impact
[48]
Post-treatment:
small impact
[48]
Significant
reduction in all
domains of QoL
Handjani et al
(2013) [49]
Iran (EMR) UMIC 50
(5 CL;
10 Psoriasis;
15 Vitiligo;
20
Pemphigus)
54% F
(Overall)
42
(Overall)
- aCL FDLQI Mean CL:
12.00 ± 4.80
Mean Psoriasis:
14.70 ± 5.01
Mean Vitiligo:
14.40 ± 5.08
Mean Pemphigus:
15.45 ± 4.70
Main concern
(CL) is time
spent looking
after partner/
relative (40%)
Hono´rio et al
(2016) [40]
Brazil
(AMR)
UMIC 44 54.5% F 51.8 - aCL WHO-QoL
Bref
Social
relationships:
74.62
Psychological:
70.55
Physical: 61.85
Environment:
59.80
Total: 66.70
Q1-2: 81.82%
rated QoL good
or very good
Hu et al
(2015) [41]
Suriname
(AMR)
UMIC 163 8.3% F
7.6% F
7 day: 33
(median)
3 day: 30
(median)
7 day:
10.7%
face
13 day:
7.7% face
aCL Skindex-29 Pre-treatment
7 day: 28.4
3 day: 31.0
Post-treatment
7 day and 3 day:
1.7
Significant
improvement
post-treatment
in both 3- and
7-day trials
Mean pre-
treatment score
for both cohorts
equates to
moderate QoL
impact (25–49.9)
[50]
Nilforoushzadeh
et al (2010) [51]
Iran (EMR) UMIC 80 100% F -
(>10)
- aCL DLQI Drug
+ Psychotherapy
Before: 10.6 ± 5.7
After: 7.7 ± 4.6
Drug alone
Before: 10.0 ± 5.1
After: 11.0 ± 5.1
Before treatment
QoL:
No impact: 0%
Small impact:
26.125%
Moderate
impact: 46.125%
Very large
impact: 25.0%
Extremely large
impact: 2.5%
(Continued)
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Table 2. (Continued)
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Measure Results Interpretation
Ranawaka et al
(2014) [52]
Sri Lanka
(SEAR)
LMIC 146 28% F 31
(median)
45% UL
25% face
20% LL
10%
trunk
aCL DLQI Mean: 5.58 Severity:
No impact:
21.0%
Small impact:
34.2%
Moderate
impact: 30.8%
Very large
impact: 13.3%
Extremely large
impact: 0.7%
Toledo et al
(2013) [53]
Brazil
(AMR)
UMIC 20 15% F 45.6 40%
exposed
areas
aCL DLQI Mean: 9.75 Severity:
No impact: 0%
Small impact:
30%
Moderate
impact: 30%
Very large
impact: 40%
Extremely large
impact: 0%
Turan et al
(2015) [36]
Turkey
(EUR)
UMIC 94
(54 CL;
40 healthy
controls)
54% F
(CL);
50% F
(Control)
7–12;
13–18
65% face aCL PedQoL 7–12
aCL:
81.31 ± 11.39
Control:
91.83 ± 4.76
13–18
aCL:
74.99 ± 13.95
Control:
80.34 ± 4.74
Young aCL
patients
significantly
worse QoL than
controls
Parents’ QoL
scores also
significantly
lower than
controls
Vares et al (2013)
[54]
Iran (EMR) UMIC 124 62.9% F 36.9
(mean)
70% UL
15% face
10% LL
aCL
(94%)
iCL
(6%)
DLQI 5.87 ± 5.96 Severity:
No impact:
26.8%
Small impact:
30.5%
Moderate
impact: 24.2%
Very large
impact: 15.3%
Extremely large
impact: 3.2%
Yanik et al
(2004) [38]
Turkey
(EUR)
UMIC 99
(33 iCL;
33 aCL;
33 healthy
controls)
50.5% F
(Overall)
18
(Overall)
70% face
30% UL
(Overall)
aCL/
iCL
DQLI aCL: 34.77 ± 8.47
iCL: 24.11 ± 8.56
QoL better in
aCL vs iCL
Moderate
correlation with
HADS-D and
DQLI (rs =
0.291)
Psychological distress
(Continued)
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Table 2. (Continued)
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Measure Results Interpretation
Bennis et al
(2017) [55]
Morocco
(EMR)
LMIC 86 42.2% F 17.7 - aCL/
iCL
Psychosocial
impact
“Yes” = 48.8%
“Maybe” = 40.7%
“No” = 10.5%
Somewhat town-
dependent:
13% “no
psychosocial
impact” in one
town; 7% “no
psychosocial
impact” in
another town
Chahed et al
(2016) [46]
Tunisia
(EMR)
LMIC 41 100% F 85% <30 93% face
54% rest
of body
iCL PLSI PLSI: 9.5 ± 6.7 A score of 10
+ denotes a high
degree of stress
in psoriatic
patients [56]
Stigma, disfigurement, and socio-economic impact
Al-Kamel (2017)
[42]
Yemen
(EMR)
LMIC 11 90.91% F 29.4 38.5%
UL
61.5%
face
aCL
72.7%
iCL
18.2%
MCL
9.1%
Stigma Social: 63.64%
Aesthetic:
63.64%
Psychological:
72.73%
1+ forms of
stigma: 90.91%
(1 form: 27.27%
2 forms: 18.18%
3 forms:
45.45%)
Abazid et al
(2012) [57]
Syria (EMR) LMIC 70 59% F 32.3 - aCL/
iCL
Disfigurement 32.9% Worst effects of
CL: Appearance
of aCL (68.6%)
and permanence
of iCL (32.9%)
Chahed et al
(2016) [46]
Tunisia
(EMR)
LMIC 41 100%F 85% <30 93% face
54% rest
of body
iCL Exclusion
Body image
Worse marital
prospects
73%
58%
75% (for M);
59% (for F)
Fernando et al
(2010) [58]
Sri Lanka
(SEAR)
LMIC 120 27% F 31.6 F: 56%
face
M: 41%
UL
aCL Isolation and
social stigma
Absent/
unable to work
18% M
25% F
55% M;
40% F
Worse with
facial lesions
Pacheco et al
(2017) [44]
Brazil
(AMR)
UMIC 24 62.5% F 38.8 100%
exposed
aCL Social
discrimination
Family
discrimination
Total: 37.5%
(F 66.6%; M
20%)
Total: 20.8%
(F: 55.5%; M 0%)
Marked gender
differences
Ramdas et al
(2016) [59]
Suriname
(AMR)
UMIC 205 10.7% F 30–39
mode
-
(face
rare)
aCL Shame, disgust
Enacted
stigma
18.5%
16%
Author reports
low stigma due
to rarity of facial
lesions
Reithinger et al
(2005) [60]
Afghanistan
(EMR)
LIC 83
(parents of
affected)
100% F - - aCL/
iCL
Disfigurement 54% felt
disfigured
children by
lesions/scars,
treatment,
exclusion
Ruoti et al (2013)
[61]
Paraguay
(AMR)
UMIC 25 28% F 49 - CL/
MCL
Shame 12.5%
Semeneh (2012)
[45]
Ethiopia
(AFR)
LIC 10 50% F 29.3 100%
face
aCL
30%
iCL
70%
Disgrace/
despair
Shame
Low self-
esteem, guilt
80%
40%
70%
(Continued)
Depression in cutaneous leishmaniasis
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007092 February 25, 2019 10 / 22
none of the four quantitative studies [34,46,52,54] providing subgroup analysis demonstrated
a statistically significant association with facial lesions and worsening psychological outcomes.
Moreover, facial iCL scars were actually associated with lower rates of depression and suicidal-
ity than those located on other parts of the body [34]. Instead, it may be more appropriate to
differentiate the visibility of lesions in future studies.
A significant number of studies focused solely on women (5/29) on the basis that women
are generally at greater risk of depression [17]. It is therefore important to consider possible
sex differences in MDD rates given that men have more reported cases of CL than women in
most endemic countries [4] Interestingly, women-only studies were found to have comparable
MDD rates as mixed sex studies, although differences in self-reported symptoms of MDD
were noted in some countries [43,44]. The reasons for these findings could perhaps be
explained by community [68], socio-economic [62], and qualitative studies [67]. For example,
whilst women are commonly more concerned by bodily appearance and marital prospects, a
roughly equal impact is placed upon men through incapacity to work and perform leadership
responsibilities [52] due to the disease.
Based on the available evidence, we conservatively estimate that 70% of individuals with
both active and inactive CL will experience some degree of psychological morbidity. This
ranges from subclinical “distress” (50%) to clinical “disorder” (20%), in accordance with the
staged model of depression [19] As such, 30% of CL patients fall into the “wellness” category of
the model, in view of regional differences in psychosocial impact [55,65] and the small number
of countries and endemic communities in which CL is less stigmatizing [59] and perceived as
less severe [69] (see Table 4).
Calculating the prevalence of inactive CL
The 2016 GBD Study provides CL prevalence estimates that account solely for aCL and that
also include MCL within them unseparated. As such, the prevalence of inactive (scarring) CL
has not been previously estimated, and is not incorporated formally into the GBD burden esti-
mates for CL. The methodology for calculating the prevalence of inactive CL has been previ-
ously described [3]. In short, our calculations are derived from the latest reported aCL
Table 2. (Continued)
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Measure Results Interpretation
Weigel et al
(1994) [62]
Ecuador
(AMR)
UMIC 208 46.6% F 35.8 - aCL/
iCL
Impact on
ability to work
Low self-
esteem
iCL: 68.9%
aCL: 61.3%
Total: 67.1%
iCL: 82.7%
aCL: 76.9%
Total: 81.3%
Men
significantly
more than
women
Woman
significantly
more than men
Yanik et al
(2004) [38]
Turkey
(EUR)
UMIC 99
(33 iCL;
33 aCL;
33 healthy
controls)
50.5% F
(Overall)
18
(Overall)
70% face
30% UL
(Overall)
aCL/
iCL
BIS aCL:
17.15 ± 11.07
iCL: 21.0 ± 8.16
Control:
38.69 ± 6.37
Body image
significantly
reduced;
moderately
correlated with
HADS-D (rs =
0.256)
DLQI = Dermatology Life Quality Index; DQLI = Dermatology Quality of Life Index; FDLQI = Family Dermatology Life Quality Index; PedQoL = Pediatric Quality of
Life; PLSI = Psoriasis Life Severity Index
https://doi.org/10.1371/journal.pntd.0007092.t002
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Table 3. Qualitative studies.
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Results
Al-Kamel
(2017) [38]
Yemen
(EMR)
LMIC 11 90.91%
F
29.4 38.5% UL
61.5%
face
aCL
72.7%
iCL
18.2%
MCL
9.1%
Fear and social isolation common;
Oldest patient (60yo) suggests stigma is
age-related;
Concerns about facial lesions and marital
prospects
Alorfi
(2016) [63]
Saudi Arabia
(EMR)
HIC 21
(Health Workers; HW)
42.86%
F
- - aCL/
iCL
Stigma from iCL noted by 8/21 HWs; 1/21
says no stigma
Parental guilt at children being affected;
All HWs agree CL has psych impact; main
concern is iCL;
1/21 HW recounts suicidal ideation in
patient;
Low self-esteem and depression common;
Fears regarding lack of effective treatment
Bennis et al
(2017) [55]
Morocco
(EMR)
LMIC 86 42.2% F 17.7 - aCL/
iCL
Low self-esteem and diminished social value
common;
Marital prospects decreased; psychological
impact can increase after treatment as scar
remains;
fear and worry concerning lack of
treatment services
da Silva et al
(2004) [64]
Brazil (AMR) UMIC 8 100% F - - aCL Fearful for health; uncertain of treatment;
feel trapped; worried about appearance
Guevara
et al (2007)
[65]
Venezuela
(AMR)
UMIC 30
(Dermatologists, health
inspectors/promoters,
nurses, social workers)
- - - aCL All participants: patients express cultural
significance of aCL and its psychological
impact, but this is not registered by
healthcare professionals due to strictly
disease-focused, biomedical approach to CL
Perception is location dependent. CL is
seen either as a “sore”, “leprosy”, or a “bite”.
Differential impact depending on how it is
perceived.
Martins
(2014) [66]
Brazil (AMR) UMIC 7 20% F 45 - aCL Strong social impact of aCL and iCL on
work, church and school
Fear, low self-esteem, depression, and
isolation frequently seen
Ramdas
et al (2016)
[59]
Suriname
(AMR)
UMIC 205 10.7% F 30–39
mode
-
(face rare)
aCL Social restrictions infrequent due to
cohesiveness of local community and
recognition of CL as a non-contagious
disease
Reyburn
et al (2000)
[67]
Afghanistan
(EMR)
LIC 84 54.8% 28 -
(usually
face/
hands)
aCL Males more affected in work and public life
(religion, work), females more affected at
home (cooking, hospitality); overall equal
impact
Most report stigmatisation; in some, strong
feelings of shame
Need to isolate CL sufferers developed into
personal rejection; lack of personal contact
particularly problematic for children
Very rare for CL to stimulate more caring
attitudes towards sufferers
(Continued)
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incidence data from WHO spanning 2006–2015 [70] that have been adjusted for underreport-
ing [10,71] and the presence of MCL within them [72–74] (see Table 5). We assume zero CL-
associated mortality and a life expectancy of 30 years with scarring; this is a conservative lon-
gevity estimate considering the life expectancy of at-risk populations in high burden countries
[74] For further information on this methodology, please see S5 Appendix.
Estimating the severity of major depressive disorder co-morbidity in
cutaneous leishmaniasis
GBD Studies differentiate the severity of episodes of MDD at three levels—mild, moderate,
and severe–each with its own disability weight [22]. Therefore, it is necessary to calculate the
severity of co-morbid MDD in CL patients to calculate the disability burden (YLD) compo-
nent of the DALY.
In the studies we identified, the mean depression scores of CL patients equated to mild
MDD, with moderate MDD scores being reached within one standard deviation in most stud-
ies. Furthermore, in a study of depression in inactive CL using Beck’s Depression Inventory,
~70% of cases with depression scored in “mild” severity [34]. Due to the relatively small sample
sizes and difficulties in comparing MDD severity from different measurement tools, we used
data from the 2010 GBD study on depressive disorders to help inform our estimates (see
Table 6). In that study, the patient MDD cohort was classified accordingly: 72.7% with Mild
severity; 16.5% with Moderate severity; and 10.8% with Severe MDD [22].
Table 3. (Continued)
Author
(Year)
Country
(WHO
Region)
Economic
Development
Sample size Sex Age Lesion
location
Disease
activity
Results
Semeneh
(2012) [45]
Ethiopia
(AFR)
LIC 10 50% F 29.3 100% face aCL 30%
iCL 70%
MDD symptoms (low self-esteem,
hopelessness, sadness) very common;
Poor QoL due to CL impact on SES, and
lack of treatment services;
Main concern is aCL, yet all left disfigured
by iCL scar;
Commonly insulted with local terms for
both iCL and aCL;
Vast majority experienced stigma,
especially in aCL phase;
Unaffected people favoured for work,
especially if facial lesions;
Marital rejection common, though some
believe not a problem
AFR = African Region; AMR = Region of the Americas; EMR = Eastern Mediterranean Region; EUR = European Region; HIC = High Income Country; SEAR = South-
East Asian Region
https://doi.org/10.1371/journal.pntd.0007092.t003
Table 4. Estimating the psychological impact of CL using the staged model of depression adapted from Patel (2017) [19].
Stage Definition CL estimate References
Wellness Absence of any sustained, distressing, emotional experiences 30% [57–59, 61]
Distress Mild to moderate distressing emotional experiences of relatively short duration 50% [46, 47, 49, 51–55, 60,
62]
Major Depressive Disorder Severely distressing experiences, lasting at least two to four weeks, with impairment of
social functioning
20% [33, 34, 36, 38, 40–45]
Recurrent Major Depressive
Disorder
Unresponsive or relapsing depressive episodes
https://doi.org/10.1371/journal.pntd.0007092.t004
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Quantifying DALYs for major depressive disorder in cutaneous
leishmaniasis
Applying the estimate for MDD severity to our prevalence estimates for cutaneous leishmania-
sis, the following YLDs were calculated: 200,000 for active CL, and 1.7 million for inactive CL
(combined total 1.9 million YLDs for CL) (see Table 7 and Table 8). We assumed no mortality
burden associated with MDD co-morbid to cutaneous leishmaniasis, and as such our YLD fig-
ures equaled the overall DALY figures (see S6 Appendix for in-depth calculations). These fig-
ures only represent the impact of co-morbid MDD in this condition and do not account for
the impact of other mental disorders such as anxiety disorders or the subclinical state of dis-
tress as per the staged model of depression [19].
Discussion
The results presented here challenge the most recent GBD estimates for the overall burden of
CL given the prevalence of mental illness reported in the literature for the condition. We high-
light the lack of reliable prevalence estimates on which GBD figures are based. We further
emphasise that, despite the increased recognition of NTDs through their inclusion as a target
within the UN Sustainable Development Goal (SDG) health targets, the burden of mental
health associated with stigmatising and chronically disabling NTDs is not appropriately fac-
tored into the calculations of overall global mental health estimates. We stress the importance
of residual disease on the continuing suffering of those with NTDs using the example of inac-
tive CL.
Indeed, inclusion of iCL increases the CL prevalence estimate 10-fold, which substantially
increases the CL disease burden in itself. However, factoring in the burden of co-morbid
MDD for both aCL and iCL further increases its overall burden to 2.2 million DALYs. This is
approximately eight times greater than the previous DALY estimate reported in the 2016 GBD
study that accounted for aCL alone [76]; this is despite our conservative estimate of only a 30
years of life expectancy post-lesion acquisition (see Table 8). Significant increases in burden
estimates were calculated previously for lymphatic filariasis [24], indicating that mental illness
is grossly unaccounted for in the NTD GBD estimates.
These findings come at a crucial time for those affected by CL, a growing number of whom
continue to be affected by war and displacement in current conflict zones. The inclusion of
iCL into prevalence estimates for CL, we argue, is necessary to enact changes at the policy level
that reflect the importance of CL to affected individuals and their communities. Moreover, the
Table 5. Estimating the prevalence of inactive CL.
Active CL
(GBD 2016) [18]
Inactive CL Total
Ratio ~10 ~90 100
Prevalence 4,320,000 33,883,900 38,203,900
https://doi.org/10.1371/journal.pntd.0007092.t005
Table 6. Estimating the severity of co-morbid MDD in cutaneous leishmaniasis.
Severity of MDD Disability Weight75 Severity of MDD
In 2010 GBD Study [22]
Mild 0.145 72.7%
Moderate 0.396 16.5%
Severe 0.658 10.8%
https://doi.org/10.1371/journal.pntd.0007092.t006
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studies we have highlighted show a clear benefit for psychological as well as physical therapies
on quality of life [41,47,51] as well as rates of depression [41] in CL patients; sadly, inability to
access any form of treatment is a commonly cited major concern for patients [45,55,63,64]. As
such, there is a very clear opportunity for national NTD programmes and partner interna-
tional NGOs to incorporate mental health care into their activities and to provide appropriate
services to tackle this growing public health problem.
Overall, the stigma and depression linked to NTDs represent areas of global health that
have only recently been highlighted [21]. From our literature review, the previous GBD esti-
mates for depression (which predict depressive disorders as a leading cause of DALYs) do not
incorporate MDD (or any other mental illness) associated with NTDs. Omitting NTDs from
such consideration of global mental health burden is significant as NTDs have been estimated
by WHO to affect over 1 billion (1 in 6) people worldwide [1].
Implications for future GBD studies
In the latest 2016 iteration of the GBD study, the psychological impact of CL scarring has been
incorporated into the disease burden estimates for the first time via a modification of disability
weights (DW) (IHME personal communication). As such, the disability burden of CL has
increased from 41,500 [77] to 273,000 [18] YLDs. Despite this modification, relying upon
DWs to capture the unique psychosocial aspects of NTDs has unfortunately led to some of the
most stigmatising (namely CL and leprosy) diseases yielding some of the lowest disability
(YLD) estimates of all the NTDs in past iterations [18,77–79]. CL is currently viewed as a “level
two disfigurement”, meaning that its DW reflects “a visible physical deformity that causes others
to stare and comment. As a result, the person is worried and has trouble sleeping and concentrat-
ing”. This corresponds to a DW of 0.067 in GBD 2016, where 0 indicates perfect health and 1
Table 7. Estimating the burden of Major Depressive Disorder in cutaneous leishmaniasis.
Active CL� Inactive CL Total CL
Prevalence 4,320,000 [18] 33,883,900 38,203,900
Prevalence with MDD (%) 20% 20% 20%
Disability Weights
(GBD 2016) [75]
0�145 (Mild MDD)
0.396 (Moderate MDD)
0.658 (Severe MDD)
0.145 (Mild MDD)
0.396 (Moderate MDD)
0.658 (Severe MDD)
0.145 (Mild MDD)
0�396 (Moderate MDD)
0.658 (Severe MDD)
YLDs
(Co-morbid MDD alone)
208,932 1,687,065 1,895,997
YLLs
(Co-morbid MDD alone)
0 0 0
DALYs
(Co-morbid MDD alone)
208,932 1,687,065 1,895,997
https://doi.org/10.1371/journal.pntd.0007092.t007
Table 8. Overall DALY estimates for cutaneous leishmaniasis (aCL and iCL).
Active CL Inactive CL Total
Physical health DALYs
(GBD 2016)76
273,000� - 273, 000
Co-morbid MDD DALYs 208,932� 1,687,065 1,895,997
Physical health +
Co-morbid MDD DALYs
481,932� 1,687,065 2,168,997
�GBD estimate includes MCL
https://doi.org/10.1371/journal.pntd.0007092.t008
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indicates death [75] Thus, we can be confident that our findings represent an unrecognized
mental disease burden of CL.
Instead, we strongly recommend that inactive (scarring) CL be included with active CL
infection in future CL prevalence estimates, and that MCL and aCL estimates be presented
separately for further information. We have shown that with inactive CL, such a large increase
in prevalence (10-fold higher) and burden of co-morbid MDD (8-fold increase) is not suffi-
ciently accounted for by simply altering the DWs for active CL given the evidence of mental ill-
ness in patients with residual scarring. As we have only included the “disorder” stage of
depressive burden in our YLD estimates, our estimate of CL-related distress (50%) using the
staged model approach to depression is not accounted for. Here adjustments to DWs for both
aCL and iCL would be justified, as a large proportion of affected individuals with both forms
of CL experience some degree of quantifiable distress or socially adverse consequences.
Finally, it is important to highlight that the 2016 GBD Study estimates of aCL incidence
[18] are almost half those of previously accepted incidence estimates published in 2012 [71].
This is despite the marked increase in CL incidence due to ongoing conflict and displacement
in the Middle East [15]. Similarly, our aCL burden estimates are based upon the 2016 GBD
Study estimates of aCL prevalence to allow for comparisons to be made. However, it is unclear
why these prevalence estimates are almost seven times lower than the annual incidence of aCL
[18] when the majority of cases of aCL self-heal within 6–12 months [2]. For these reasons, we
did not include GBD estimates in our calculations of iCL prevalence.
Study limitations
Although our study is the first to generate prevalence estimates of inactive (scarring) CL, we
were cautious of the life span of patients with iCL lesions, which is currently unknown. Whilst
the majority of CL infections occur in older children and young adults [4] we took a conserva-
tive approach to our iCL prevalence estimates by assuming just 30 years lived with residual
scars. Nevertheless, given that the majority of aCL cases occur in the young and working adult
populations, this figure could be significantly higher. We also conservatively assume no mor-
tality burden with CL, yet suicidal risk and ideation has been noted in both aCL and iCL
patients [34,63].
Secondly, we acknowledge our failure to include prevalence and isolated burden estimates
for co-morbid MDD in MCL. As discussed, MCL prevalence (and YLD burden) has not been
separated from that of aCL in GBD Studies. A further complicating factor is the mortality rate
of MCL, which has not been established and consequently prevented us from generating reli-
able MCL prevalence estimates from WHO incidence data. Nevertheless, the experience of
shame in CL patients [45,59] was surprisingly higher than that found in a study of mixed MCL
and CL patients [61]. However, in a study of MCL patients alone [80], notably those with
severe disease, rates of social exclusion and reduced quality of life were comparable to those
found in CL patients [45,52,54,62]. It is possible that the prevalence of co-morbid MDD in
MCL patients is similar to that of aCL patients (~20% of cases), meaning that our aCL burden
estimates may be relatively unaffected by the presence of MCL cases within them.
This is the first study to estimate the burden of a co-morbid mental disorder in aCL and
iCL. One major limitation of our estimates is the evidence underpinning them. We recognize
that our 29 studies represent only a relatively small proportion of the global CL caseload. Nev-
ertheless, our systematic literature review has identified the majority of evidence of psychologi-
cal impact in CL patients to date, and doubled the evidence of previous recent attempts [81].
Moreover, these studies represent a range of geographically diverse populations across several
levels of economic development. In our analysis, studies quantifying MDD using robust and
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internationally recognised criteria (i.e. DSM) were given the most weight in generating our
final estimates of MDD co-morbid to CL. We were also selective and chose to only utilize stud-
ies of CL patients and their care providers. In order to minimize the effects of bias we
accounted for patient- and disease-specific variables such as sex, age, lesion location, and
country of study. As results for co-morbid MDD were comparable when these variables
changed, we were confident that none of these variables could have significantly biased our
overall estimates.
Finally, whilst depressive disorders represent the most prevalent form of mental disorder
worldwide, CL patients are affected by a range of other mental disorders, which have not been
included in our estimates. Indeed, CL patients may be at even greater risk of multiple mental
disorders [33]. These include generalised anxiety disorder, which may predominate in the
active CL phase [36,38] post-traumatic stress disorder [33] and mixed anxiety and depressive
disorder [41], the latter of which is not independently considered within the GBD framework
at present.
Conclusion
Social stigma, disfigurement, and patient suffering are some of the most identifiable features of
NTDs, as emphasized by the case of cutaneous leishmaniasis. However, the suffering of those
with active infection as well as those who remain disfigured by NTDs post-infection is not ade-
quately factored into NTD programmes or burden estimates. We reason that there is value in
striving for both goals by placing the individual at the centre of such programmes to achieve
the holistic care of individuals affected by NTDs. After all, focusing solely on the disease alone
ignores the characteristic disability associated with NTDs such as cutaneous leishmaniasis, lep-
rosy, and filariasis, and risks leaving affected individuals behind.
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